|
Mar 14
|
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
|
|
Mar 14
|
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 13
|
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
|
|
Mar 13
|
Q4 2024 Nektar Therapeutics Earnings Call
|
|
Mar 13
|
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Mar 13
|
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Mar 12
|
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
|
|
Mar 12
|
Nektar: Q4 Earnings Snapshot
|
|
Mar 12
|
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 12
|
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Jan 31
|
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Jan 31
|
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
|
|
Jan 27
|
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
|
|
Jan 4
|
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership
|